Comparative Bioavailability and Tolerability of a Single 2-mg Dose of 2 Repaglinide Tablet Formulations in Fasting Healthy Chinese Male Volunteers: An Open-Label Randomized-Sequence 2-Period Crossover Study

摘要

BackgroundRepaglinide, an oral insulin secretagogue, was the first meglitinide analogue to be approved for use in patients with type 2 diabetes mellitus.